MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Atara Biotherapeutics Interest Expense 2011-2026 | ATRA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Atara Biotherapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.62 M | 5.28 M | 373 K | 367 K | 2.45 M | 4.72 M | 6.37 M | 2.03 M | 2.2 M | 1.22 M | 125 K | 12 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.37 M | 12 K | 2.48 M |
Quarterly Interest Expense Atara Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 909 K | 972 K | 1.02 M | - | 1.18 M | 1.26 M | 1.15 M | - | 1.4 M | 1.38 M | 1.34 M | - | 123 K | 129 K | 4 K | - | 148 K | 225 K | -90 K | - | 364 K | 497 K | 1.19 M | - | 661 K | 1.21 M | 1.63 M | - | 1.86 M | 1.74 M | 1.01 M | - | 564 K | 481 K | 509 K | - | 576 K | 605 K | 503 K | - | 380 K | 163 K | 153 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.86 M | -90 K | 765 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | USA |
 |
ADMA Biologics
ADMA
|
-212 K | $ 15.6 | -5.71 % | $ 3.72 B | USA |
 |
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.55 | -2.34 % | $ 1.06 B |  Canada |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
-133 K | $ 20.14 | 1.41 % | $ 2.54 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
-4.03 M | $ 75.28 | -1.63 % | $ 1.45 B | USA |
 |
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.47 | -9.81 % | $ 375 M |  Britain |
 |
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
103 K | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
1.6 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-15.9 M | $ 160.48 | -2.19 % | $ 7.98 B | USA |
 |
BridgeBio Pharma
BBIO
|
43.1 M | $ 65.44 | -1.65 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | USA |
 |
BioLineRx Ltd.
BLRX
|
9.07 M | $ 2.75 | -2.14 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
15.3 M | $ 60.53 | 0.17 % | $ 11.6 B | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
1.26 M | $ 2.98 | -7.03 % | $ 1.07 M | USA |
 |
Capricor Therapeutics
CAPR
|
399 K | $ 25.34 | -0.65 % | $ 679 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
3.39 M | $ 8.02 | -4.75 % | $ 34.7 M | USA |